Top Story

Ruxolitinib superior to standard therapy for polycythemia vera

January 28, 2015

Patients with polycythemia vera who were resistant to or intolerant of hydroxyurea therapy demonstrated better controlled hematocrit levels, reduced spleen volume and improved symptoms when they received ruxolitinib compared with standard therapy, according to study results.

“Polycythemia vera is a disease of the blood and bone marrow that results in too many blood cells, particularly red blood cells, that lead to an increased risk of thrombosis,” Srdan Verstovsek, MD, PhD, professor in the department of leukemia at The University of Texas MD Anderson Cancer Center and a HemOnc Today Editorial Board member, told HemOnc Today. “In addition to phlebotomy and aspirin, a majority of patients require cytoreductive therapy to control blood cell count and signs and symptoms of the disease, and hydroxyurea is the standard first medication to use. Up to 20% to 25% of patients do not do well on hydroxyurea, are resistant to or intolerant of it or lose response over time, and alternative therapeutic options are limited.”

Gregory Armstrong, MD In the Journals

Variation in risk for late mortality among pediatric cancer survivors can persist up to 20 years post-diagnosis

January 28, 2015
Although all survivors of pediatric cancer face increased risk for death, the risk is reduced as survivors age through childhood and young adulthood, according to study…
In the Journals

Confocal laser endomicroscopy improved detection of biliary cancer

January 28, 2015
When combined with tissue sampling, using probe-based confocal laser endomicroscopy during endoscopic retrograde cholangio-pancreatography diagnosed cholangiocarcinoma…

Clinical trial of procedure to relieve spinal cancer pain launched

January 28, 2015
Loyola University Medical Center has launched the first clinical trial in the United States to test a new combination treatment that delivers radiation directly to the…
Toni K. Choueiri, MD In the Journals

PD-L1 expression, CD8+ T-cell counts associated with shorter OS in mRCC

January 28, 2015
Higher levels of PD-L1 expression, as well as PD-L1 expression plus tumor CD8+ T-cell counts, were linked to shorter survival in patients with metastatic renal cell…
More News Headlines »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan